164 related articles for article (PubMed ID: 17786440)
1. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.
Nabekura T; Nagasawa T; Nakauchi H; Onodera M
Cancer Immunol Immunother; 2008 May; 57(5):611-22. PubMed ID: 17786440
[TBL] [Abstract][Full Text] [Related]
2. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
3. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
4. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
6. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells.
zum Büschenfelde CM; Metzger J; Hermann C; Nicklisch N; Peschel C; Bernhard H
J Immunol; 2001 Aug; 167(3):1712-9. PubMed ID: 11466395
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
[TBL] [Abstract][Full Text] [Related]
8. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
9. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.
Triulzi C; Vertuani S; Curcio C; Antognoli A; Seibt J; Akusjärvi G; Wei WZ; Cavallo F; Kiessling R
Cancer Res; 2010 Oct; 70(19):7431-41. PubMed ID: 20823150
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
[TBL] [Abstract][Full Text] [Related]
12. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.
Nabekura T; Otsu M; Nagasawa T; Nakauchi H; Onodera M
Mol Ther; 2006 Feb; 13(2):301-9. PubMed ID: 16311073
[TBL] [Abstract][Full Text] [Related]
13. Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2.
Suresh K; Scheid E; Klotz L; Venkateswaran V; Gauldie J; Foley R
Int J Oncol; 2011 Oct; 39(4):907-13. PubMed ID: 21769423
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor.
Tegerstedt K; Franzén A; Ramqvist T; Dalianis T
Cancer Immunol Immunother; 2007 Sep; 56(9):1335-44. PubMed ID: 17268793
[TBL] [Abstract][Full Text] [Related]
15. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
16. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
17. HER2 dendritic cell vaccines.
Morse MA; Clay TM; Colling K; Hobeika A; Grabstein K; Cheever MA; Lyerly HK
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S164-72. PubMed ID: 12620155
[TBL] [Abstract][Full Text] [Related]
18. Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.
Qiu SJ; Lu L; Qiao C; Wang L; Wang Z; Xiao X; Qian S; Fung JJ; Ye SL; Bonham CA
J Cancer Res Clin Oncol; 2005 Jul; 131(7):429-38. PubMed ID: 15818505
[TBL] [Abstract][Full Text] [Related]
19. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
